Containing Solid Synthetic Polymers Patents (Class 424/497)
-
Publication number: 20140255503Abstract: The present invention refers to oral solid pharmaceutical compositions comprising concentrate omeprazole pellets, processes for the preparation of the same and their use as medicaments, more particularly for the treatment and/or prophylaxis of a gastrointestinal disorder.Type: ApplicationFiled: October 31, 2012Publication date: September 11, 2014Inventors: Jaume Sangrà Perez, Cristina Alcocer Aranzana
-
Patent number: 8828429Abstract: The present invention relates to a controlled release capsule preparation for oral administration, which contains (i) a granule containing a physiologically active substance which is a compound represented by the formula: wherein n is an integer of 1 to 3, and Ar is an aromatic ring optionally having substituent(s), or a salt thereof, and a hydrophilic polymer, and coated with an enteric coating agent and the like, and (ii) a fluidizer. According to the present invention, a controlled release composition for oral administration of an imidazole derivative, which has steroid C17,20-lyase inhibiting activity and which has remarkably improved sustainability of the blood concentration, is provided.Type: GrantFiled: March 3, 2006Date of Patent: September 9, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Hajime Ishida, Yukihiro Nomura
-
Patent number: 8828440Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: GrantFiled: March 16, 2012Date of Patent: September 9, 2014Assignee: Flexion Therapeutics, Inc.Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Publication number: 20140249031Abstract: The present invention relates to crystalline particles [particularly organic particles or agrochemical particles] coated with micelles of copolymers, to compositions comprising such particles, to a process for preparing the coated particles and to uses of the particles and the compositions [for example to produce surface coatings with high loadings of copolymer and uses of products derived therefrom].Type: ApplicationFiled: July 3, 2012Publication date: September 4, 2014Applicant: SYNGENTA LIMITEDInventors: Patrick Joseph Mulqueen, Niall Rae Thomson, Simon Richard Biggs, Nelly Chagneux, Mathieu Edmond Rene Dubois, Prodip Sarker, Shane Scanlon
-
Publication number: 20140248341Abstract: Pharmaceutical formulations that resist ethanol-induced dose dumping and methods of use thereof.Type: ApplicationFiled: April 29, 2014Publication date: September 4, 2014Applicant: ALKERMES PHARMA IRELAND LIMITEDInventors: Gary Liversidge, David Manser, Shah Hardik, Stephen B. Ruddy, Gurvinder S. Rekhi
-
Patent number: 8821935Abstract: The present invention is directed to microcapsules for reliably modified release and adapted to industrial reproduction of an active principle hardly water-soluble, other than anti-hyperglycemia agents. Each of said microcapsules comprises a core of hardly soluble active principle and a coating film applied on the core. Their mean diameter is less than 1000 microns. The coating film contains a film-forming polymer (PI) insoluble in gastrointestinal tract fluids, a water-soluble polymer (P2), a plasticizer (PL), and optionally a lubricating surfactant (TA). Said coating film represents at least 4% p/p of dry matter of their total weight, and its components P1, P2, PL satisfy the following characteristics: dry weight mass fraction of PI relative to the total coating weight ranging between 40 and 90%; dry matter weight fraction of PL/P1+P2 ranging between 15 and 60%; dry matter weight fraction of PL/P1+P2 ranging between 1 and 30%.Type: GrantFiled: October 20, 2006Date of Patent: September 2, 2014Assignee: Flamel TechnologiesInventors: Florence Guimberteau, Catherine Castan, Rémi Meyruiex, Gérard Soula
-
Publication number: 20140242165Abstract: A biocompatible carrier for delivery of a therapeutic substance or an active agent is disclosed. The carrier contains a bioadhesive material allowing for increased residence time of the active agent at the treatment site.Type: ApplicationFiled: May 7, 2014Publication date: August 28, 2014Applicant: Abbott Cardiovascular Systems Inc.Inventor: Wouter E. Roorda
-
Publication number: 20140242162Abstract: The invention relates to extended release pharmaceutical formulations in form of multiparticulates comprising 40-O-(2-hydroxy)ethyl-rapamycin, to dosage forms which comprise said pharmaceutical formulations, to methods of preparing said pharmaceutical formulations and said dosage forms, to uses of said pharmaceutical formulations and said dosage for the manufacture of a medicament for the treatment or prevention of diseases or conditions responsive to inhibition of mTOR signaling pathway, such as for instance proliferative diseases or immunosuppression.Type: ApplicationFiled: October 3, 2012Publication date: August 28, 2014Inventors: Anke Diederich, Kurt Liechti, Peter Kuehl, Wing Cheung
-
Publication number: 20140227197Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 5 to 8 hours or longer, followed by a prolonged release.Type: ApplicationFiled: April 17, 2014Publication date: August 14, 2014Inventors: David Lickrish, Feng Zhang
-
Publication number: 20140227351Abstract: Taste masked multi-layered particles include an inert core, one or more coating layer(s) comprising a pharmaceutically active ingredient and a binder, an intermediate coating layer (seal coating) free from a low molecular weight water-soluble ionic compound and including a water-soluble pharmaceutical film-forming compound selected from (i) HPMC and PEG or (ii) PVP, and an outer coating layer (final or taste masking coating) free from a low molecular weight water-soluble ionic compound and comprising (i) a poly(meth)acrylate or (ii) a mixture including 60-90% (w/w) EC and 10-40% (w/w) HPMC, where the pharmaceutically active ingredient is water-soluble and includes either at least one basic group and/or a bitter taste. Further disclosed are methods for the production of such particles and pharmaceutical compositions including such particles.Type: ApplicationFiled: April 16, 2014Publication date: August 14, 2014Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventors: Martin FOLGER, Stefan LEHNER, Annette GRAVE, Norbet POELLINGER, Randolph SEIDLER
-
Publication number: 20140227358Abstract: The present invention provides various pharmaceutical compositions comprising an S1P receptor modulator, e.g. an S1P receptor agonist. In one aspect, there is provided a pharmaceutical composition having a coating. In other aspects, rapid disintegrating compositions are provided. In a further aspect, a pharmaceutical composition which is free of sugar alcohols is provided. In another aspect, the invention provides a pharmaceutical composition comprising a coating comprising an S1P receptor modulator.Type: ApplicationFiled: April 17, 2014Publication date: August 14, 2014Applicant: NOVARTIS AGInventors: Michael AMBUHL, Jutta BEYER, Begona CARRENO-GOMEZ, Colleen RUEGGER, Stephen VALAZZA
-
Patent number: 8802157Abstract: A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form.Type: GrantFiled: July 16, 2013Date of Patent: August 12, 2014Assignee: Depomed, Inc.Inventors: Bret Berner, Sui Yuen Eddie Hou
-
Patent number: 8802156Abstract: A pharmaceutical composition containing a sulfated glycosaminoglycan drug and a polycationic polymer or copolymer wherein the proportion of ammonium groups in the pharmaceutical composition is between 0.01-2.0 ?mol ammonium groups/mg pharmaceutical composition, the proportion of glycosaminoglycan in the pharmaceutical form is between 15% to 50% w/w, and the pharmaceutical composition possesses a moisture content of 10% wt or less. A pharmaceutical dosage form containing the pharmaceutical composition, and their use for the treatment of diseases or disorders therapeutically responsive to the glycosaminoglycan.Type: GrantFiled: July 29, 2011Date of Patent: August 12, 2014Assignee: Laboratorios Farmacéuticos Rovi, S.A.Inventors: Guillermo Franco Rodriguez, Ibon Gutierro Aduriz
-
Publication number: 20140220148Abstract: The present invention relates to pharmaceutical compositions, food supplement compositions and cosmetic compositions comprising diaminooxidase, and to the use thereof.Type: ApplicationFiled: April 4, 2014Publication date: August 7, 2014Applicant: SCIOTEC DIAGNOSTIC TECHNOLOGIES GMBHInventors: Albert MISSBICHLER, Franz GABOR, Herwig REICHL
-
Publication number: 20140212483Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.Type: ApplicationFiled: March 31, 2014Publication date: July 31, 2014Inventors: David Lickrish, Feng Zhang
-
Patent number: 8791285Abstract: An activatable nanoprobe is provided having a core component and an active agent associated with the core component via a bond configured to be cleaved upon exposure to an endogenous compound.Type: GrantFiled: June 11, 2012Date of Patent: July 29, 2014Assignee: University of Central Florida Research Foundation, Inc.Inventors: Swadeshmukul Santra, James Turkson
-
Publication number: 20140205672Abstract: A controlled release composition for oral administration, which comprises a physiologically active substance which is a compound represented by the formula: wherein n is an integer of 1 to 3, and Ar is an aromatic ring which may be substituted, or a salt thereof, and a hydrophilic polymer, or a controlled release composition for oral administration, wherein a core containing the physiologically active substance is coated with a coating layer containing a polymer, is provided.Type: ApplicationFiled: January 17, 2014Publication date: July 24, 2014Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Shigeo Yanai, Kazumichi Yamamoto
-
Patent number: 8784870Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with free-radical modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).Type: GrantFiled: July 21, 2009Date of Patent: July 22, 2014Assignees: Otonomy, Inc., The Regents of the University of CaliforniaInventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Michael Christopher Scaife, Benedikt Vollrath, Sergio G. Duron, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
-
Publication number: 20140199388Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.Type: ApplicationFiled: March 14, 2014Publication date: July 17, 2014Applicant: Forward Pharma A/SInventors: Henrik NILSSON, Florian Schoenharting, Bernd W. Mueller, Joseph R. Robinson
-
Patent number: 8778396Abstract: This invention relates to an orally administrable, gastroretentive pharmaceutical dosage form which contains at least one pharmaceutically active ingredient and at least one polymeric adjuvant. The adjuvant serves to retain the dosage form in a selected region of the gastrointestinal tract for sufficient time for the pharmaceutically active ingredient to be released and absorbed. Ideally the dosage form will contain two or more pharmaceutically active ingredients which are delivered to different regions of the gastrointestinal tract.Type: GrantFiled: June 3, 2009Date of Patent: July 15, 2014Assignee: University of the Witwatersrand, JohannesburgInventors: Viness Pillay, Yahya Choonara, Caragh Murphy, Sarashnee Moonisami
-
Publication number: 20140193492Abstract: The present invention concerns a new method of preparing granules comprising 5-aminosalicylic acid and a new method of preparing a pharmaceutical composition for the treatment of ulcerative colitis or Crohn's disease by oral administration comprising as active ingredient 5-aminosalicylic acid.Type: ApplicationFiled: December 19, 2013Publication date: July 10, 2014Applicant: Ferring B.V.Inventor: Svenn Kluver Jepsen
-
Publication number: 20140193497Abstract: A pharmaceutical composition is described which includes diclofenac as an active ingredient. The pharmaceutical composition further includes a (meth)acrylic polymer which has a specific solubility and/or a particular functional group in one polymer component.Type: ApplicationFiled: April 19, 2013Publication date: July 10, 2014Applicant: Glatt AGInventors: Frédéric Gerber, Marie Guhmann, Norbert Pöllinger
-
Publication number: 20140193504Abstract: The present disclosure generally relates to polymer-drug systems, and more particularly to nanoscopic particles comprising amphiphilic block copolymers conjugated, physically encapsulated, or otherwise combined with chemotherapeutic agents along a selective region or regions of the backbone of the copolymer, so as to package the chemotherapeutic agent in selective domains within each nanoscopic particle, as well as to methods for making such particles, and applications and methods for using such particles, including in the formation of polymer micelles.Type: ApplicationFiled: October 1, 2013Publication date: July 10, 2014Inventors: Karen Wooley, Jiong Zou, Mahmoud El Sabahy, Shiyi Zhang, Fuwu Zhang
-
Publication number: 20140186450Abstract: The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease.Type: ApplicationFiled: December 4, 2013Publication date: July 3, 2014Applicant: ALFA WASSERMANN S.P.A.Inventors: Giuseppe Claudio VISCOMI, Ernesto PALAZZINI, Villiam ZAMBONI, Maria Rosaria PANTALEO
-
Publication number: 20140186451Abstract: New compositions and methods are described for modulating the rate of conversion of ethylene bisdithiocarbamate fungicides, such as mancozeb, into ethylene bis-isothiocyanate sulfide (EBIS).Type: ApplicationFiled: December 27, 2013Publication date: July 3, 2014Inventors: Min Zhao, Lei Liu, J. Todd Mathieson, Robert J. Ehr, Maria E. Rodriguez Rosas
-
Publication number: 20140186449Abstract: A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.Type: ApplicationFiled: March 6, 2014Publication date: July 3, 2014Inventors: Yohko AKIYAMA, Takashi KURASAWA, Hiroto BANDO, Naoki NAGAHARA
-
Publication number: 20140186448Abstract: A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.Type: ApplicationFiled: March 6, 2014Publication date: July 3, 2014Inventors: Yohko AKIYAMA, Takashi KURASAWA, Hiroto BANDO, Naoki NAGAHARA
-
Publication number: 20140178484Abstract: A multi-particulate pharmaceutical composition suitable for administration in a sprinkle dosage form said particles being less than 2 mm in diameter and comprising a) inert core particles b) an inner layer surrounding said inert core particles, said layer comprising atorvastatin calcium, methyl methacrylate butyl methacrylate-dimethylaminoethyl methacrylate copolymer and disintegrant and c) an outer taste masking layer surrounding the inner layer, said outer layer comprising methyl methacrylate butyl methacrylate-dimethylaminoethyl methacrylate copolymer.Type: ApplicationFiled: May 16, 2012Publication date: June 26, 2014Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Yashoraj Rupsinh Zala, Nitin Dharmadhikari, Majed Mohammed Khan, Manisha Nabar
-
Publication number: 20140178485Abstract: The present invention concerns polymeric-enveloped microparticles including at least one HASE type acrylic copolymer, at least one solid-liquid phase change material with a phase transition temperature ranging from 20 to 90° C., and at least one active agent. In particular, the microparticles include at least one HASE type acrylic copolymer including at least one anionic monomer with a polymerizable vinyl group and a carboxyl group, at least one non-ionic hydrophobic monomer with a polymerizable vinyl group, and at least one alkoxylated associative macromonomer with a polymerizable vinyl group and a hydrophobic hydrocarbon chain.Type: ApplicationFiled: December 19, 2013Publication date: June 26, 2014Applicant: COATEXInventors: Clementine CHAMPAGNE, JEAN-MARC SUAU, OLIVIER GUERRET
-
Patent number: 8758827Abstract: A local system for the release of active principle is described which consists of approximately spherical or rotation symmetrical bodies which are composed essentially of polymethyl methacrylate or polymethyl methacrylate co-methyl acrylate, zirconium dioxide or barium sulphate and one or more pharmaceutical active principles, in particular antibiotics, and which are produced by radical polymerization, radical polymerization activators effective in the temperature range of 10-80° C. or residues of these polymerization activators from the groups of aromatic amines, heavy metal salts and barbiturates not being contained therein.Type: GrantFiled: November 18, 2010Date of Patent: June 24, 2014Assignee: Heraeus Medical GmbHInventors: Klaus-Dieter Kuhn, Sebastian Vogt
-
Publication number: 20140171328Abstract: A novel composite including one or more core units, each core unit including a specified active agent and having pH responsive, vinylic copolymer coating, to a process for the preparation of such a composite, to formulations including the same and their use in a variety of industrial applications.Type: ApplicationFiled: April 13, 2012Publication date: June 19, 2014Applicant: REVOLYMER (U.K.) LIMITEDInventors: Stephen Armstrong, Terence Cosgrove, John Jeffrey Gerrard, Melanie Jane Hughes, David Alan Pears
-
Patent number: 8753686Abstract: To provide surface-treating agents that can provide excellent hydrophobicity to powder and can improve its rinsability, to provide surface-treated powders that are treated with the surface-treating agent, and to provide cosmetics that comprise the surface-treated powder. A surface-treating agent consisting of a polymer which comprises a monomer (A) represented by the general formula (1) described below as a constituent monomer. (wherein R1 represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, R2 represents an alkylene group having 4 to 22 carbon atoms, X1 represents an —NH— group or an oxygen atom, and M1 represents a hydrogen atom or a monovalent inorganic or organic cation.Type: GrantFiled: May 23, 2011Date of Patent: June 17, 2014Assignee: Shiseido Co., Ltd.Inventors: Shuji Nishihama, Isamu Kaneda, Atsushi Sogabe, Tomo Osawa, Shin-ichi Yusa
-
Publication number: 20140161891Abstract: The present invention is related to a composition of PI3K inhibitor, comprising: 0.01˜10 mg of PI3K inhibitor; 10˜500 mg of poly(lactic-co-glycolic acid) (PLGA) which is encapsulated onto the surface of the PI3K inhibitor and the surface is non-modified by a modifier; and the composition has a size of 10˜1000 nm. Thereby, an excellent effect on suppressing the growth of tumor cells will be achieved by the encapsulation of PI3K inhibitor into PLGA nanomaterials without any modifier on its surface, the optimization of a ratio of PI3K inhibitor to PLGA, and the accordingly slow release of the composition.Type: ApplicationFiled: December 10, 2012Publication date: June 12, 2014Inventors: WU-CHOU SU, DAR-BIN SHIEH, CHEN-SHENG YEH, CHIA-CHENG HOU
-
Publication number: 20140161892Abstract: The present invention relates to nanoparticles for encapsulating compounds, the preparation and uses thereof, said nanoparticles being based on half (C1-C4) alkyl esters of poly (methyl vinyl ether-co-maleic anhydride) (PVM/MA) copolymers. Said nanoparticles can encapsulate or incorporate a product of interest for use in the agricultural, cosmetic, food or pharmaceutical fields.Type: ApplicationFiled: April 16, 2012Publication date: June 12, 2014Applicant: BIONANOPLUS, S.L.Inventors: Hesham H.A. Salman, Izaskun Goni Azcarate
-
Publication number: 20140161893Abstract: Core-shell polymer blend particles are described. The particles include a pH-responsive polymeric shell and a pH-irresponsive polymeric core. The core can include a biodegradable hydrolysable polymer and the shell can include a pH-responsive copolymer that can include constitutional units that are cationic and/or anionic at physiological pH. The core-shell polymer blend particles can allow the controlled delivery of agents into a plurality of distinct intracellular compartments.Type: ApplicationFiled: January 10, 2014Publication date: June 12, 2014Applicant: University of Washington through its Center for CommercializationInventors: Hong Shen, Patrick S. Stayton, Anthony Convertine, Kenny K. Tran
-
Patent number: 8747904Abstract: The present invention provides micelles having a polynucleotide encapsulated therein, the micelle comprising copolymers comprising hydrophobic moieties in a cationic complexing block. The invention further provides methods of preparing and using said micelles, and compositions thereof.Type: GrantFiled: August 21, 2012Date of Patent: June 10, 2014Assignee: Intezyne Technologies, Inc.Inventors: Janni Mirosevich, Gregoire Cardoen, Kevin N. Sill, Habib Skaff
-
Patent number: 8747890Abstract: Compositions and methods for treating systemic diseases by intravenous administration of formulations of synthesized curcumin (diferuloylmethane) and concomitantly a calcium channel blocker to human subjects with neoplastic and neurodegenerative diseases are disclosed herein. The diseases are treated by prolonged administration of sub-optimal doses of liposomal curcumin or polymeric nanocurcumin or the sustained release curcumin from PLGA nanocurcumin at dosages below systemic hemolytic thresholds concomitantly with or without calcium channel blockers.Type: GrantFiled: November 19, 2010Date of Patent: June 10, 2014Assignee: Signpath Pharma Inc.Inventor: Lawrence Helson
-
Publication number: 20140154328Abstract: The invention relates to an oral pharmaceutical composition comprising coated particles of a complex of at least one active agent with an ion-exchange resin, wherein said particles are coated with a bioadhesive coating layer comprising at least one bioadhesive material. The invention also relates to a process for preparing the oral pharmaceutical composition.Type: ApplicationFiled: April 5, 2012Publication date: June 5, 2014Inventor: Cvjetko Brkicic
-
Publication number: 20140147509Abstract: A particle is disclosed. The particle comprising: (i) at least one inner core which comprises a solid matrix of nutrients for microorganism growth; (ii) an inner membrane being fabricated from a water-soluble polymer, the inner membrane surrounding the inner core and a population of dried microorganisms; and (iii) an outer porous membrane surrounding the inner membrane, the outer porous membrane being insoluble in water. Methods of generating same, propagating microorganisms within and uses of same are also disclosed.Type: ApplicationFiled: February 2, 2014Publication date: May 29, 2014Inventor: Ofir MENASHE
-
Patent number: 8734851Abstract: The present invention provides implantable medical devices coated with polyelectrolyte assemblies that are fabricated by layer-by-layer deposition of nucleic acid and polycation. Such devices facilitate the local delivery of a nucleic acid contained in the polyelectrolyte assembly into a cell or tissue at an implantation site. Also provided are methods of fabricating and using implantable medical devices according to the invention.Type: GrantFiled: May 1, 2006Date of Patent: May 27, 2014Assignee: Wisconsin Alumni Research FoundationInventors: David M. Lynn, Jingtao Zhang, Christopher M. Jewell, Nathaniel J. Fredin
-
Patent number: 8734852Abstract: A controlled release parenteral formulation for treatment of pain and inflammation is provided. The formulation includes an effective amount of: one or more active drug moiety. The drug moiety is selected from a group comprising aceclofenac or diclofenac or a combination thereof; One or more solvent moiety selected from a group comprising one or more of ethyl acetate, triacetin, di methyl iso sorbide, DMA, DMSO, PEG, PVP, PVA, Span 80, DCM, Benzyl alcohol, acetone or a combination thereof. The formulation, upon administration, has a release profile including an immediate burst release and the burst release is followed by a slow release of at least 18 to 24 hrs. The immediate burst release and the slow release of the drug moiety remains within the therapeutic window of the drug moiety.Type: GrantFiled: January 5, 2012Date of Patent: May 27, 2014Inventor: Manu Chaudhary
-
Publication number: 20140141092Abstract: The invention discloses a gastric resistant pharmaceutical or nutraceutical composition, comprising a core, comprising a pharmaceutical or nutraceutical active ingredient and a gastric resistant coating layer onto the core, wherein the gastric resistant coating layer comprises at least 30% by weight of a (meth)acrylate copolymer comprising polymerized units of 10 to 40% by weight of acrylic or methacrylic acid, 10 to 80% by weight of a C4- to C18-alkyl ester of acrylic or methacrylic acid and optionally 0 to 60% by weight of another vinylic monomer, whereby the release of the pharmaceutical or nutraceutical active ingredient is not more than 10% under in-vitro conditions at pH 1.2 after 2 hours in medium according to USP with and without the addition of 20% (v/v) ethanol.Type: ApplicationFiled: June 12, 2012Publication date: May 22, 2014Applicant: Evonik Roehm GmbHInventors: Jan Hendrik Schattka, Christian Meier, Herbert Jung, Hedi Krachtus, Jessica del Rosario Ferrand
-
Patent number: 8722650Abstract: An oral dosage form has the following: an amount of minocycline selected from the group consisting of 55 mg, 80 mg, and 105 mg; an amount of lactose monohydrate; an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is at least 8.3 to about 9.8% hydroxypropoxylated. The minocycline in the oral dosage form has a dissolution profile or release rates about 35% to about 50% in 1 hour, about 60% to about 75% in 2 hours, and at least about 90% in 4 hours. There is also provided a method of treating acne in a human and a method of assisting a physician in prescribing a dose of minocycline for the treatment of acne.Type: GrantFiled: August 23, 2010Date of Patent: May 13, 2014Assignee: Medicis Pharmaceutical CorporationInventors: Mitchell Wortzman, R. Todd Plott, Steven B. Newhard, David Watt
-
Publication number: 20140127309Abstract: The present invention meets one or more of the above needs and is a composition comprising plurality of capsules wherein the capsules comprise: a core of one or more highly polar liquids; one or more polar active materials dissolved in or dispersed in one or more highly polar liquids; a mixture of one or more polymers and one of more highly polar liquids; or a mixture of one or more polymers, one or more highly polar liquids and one or more polar active materials, and a shell comprising, particles in a polymer matrix or particles; wherein the thickness of the shell is sufficient to prevent passage of the highly polar liquid or the active material through the shell or to control the rate passage of the highly polar liquid or the active material through the shell with the proviso that the one or more polymers may be located in the core, in the polymer matrix of the shell or both.Type: ApplicationFiled: May 31, 2012Publication date: May 8, 2014Applicants: ROHM and HAAS COMPANY, Dow Global Technologies LLCInventors: Ian J. Drake, Andrew Hughes, Christopher J. Tucker, Thomas H. Kalantar, Joshua S Katz
-
Publication number: 20140127308Abstract: A composition comprising microcapsules, the microcapsules containing both live mammalian ovarian granulosa cells and live mammalian ovarian theca cells, is described. In some embodiments, the granulosa cells and the theca cells are contained in separate microcapsules in the composition; in some embodiments, the granulosa cells and the theca cells are contained together in the same microcapsules in the composition The composition is can be used for estrogen, and optionally also progesterone, delivery, and hence is preferably free or essentially free of oocytes. Methods of using the same and pharmaceutical formulations containing the same are also described.Type: ApplicationFiled: February 21, 2012Publication date: May 8, 2014Applicant: Wake Forest University Health SciencesInventors: Emmanuel Opara, James J. Yoo, Justin M. Saul, Sittadjody Sivanandane, Anthony Atala
-
Patent number: 8715728Abstract: An extended release pellet comprising an active ingredient selected from pramipexole and the pharmaceutically acceptable salts thereof, and at least one release-modifying excipient.Type: GrantFiled: December 3, 2009Date of Patent: May 6, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Thomas Friedl, Rolf-Stefan Brickl
-
Publication number: 20140120168Abstract: Embodiments of the present invention relate to a metastable silver nanoparticle composite, a process for its manufacture, and its use as a source for silver ions. In various embodiments, the composite comprises, consists essentially of, or consists of metastable silver nanoparticles that change shape when exposed to moisture, a stability modulant that controls the rate of the shape change, and a substrate to support the silver nanoparticles and the modulant.Type: ApplicationFiled: October 25, 2013Publication date: May 1, 2014Inventors: STEVEN J. OLDENBURG, RICHARD K. BALDWIN
-
Publication number: 20140112987Abstract: The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease.Type: ApplicationFiled: October 2, 2013Publication date: April 24, 2014Applicant: ALFA WASSERMANN S.P.A.Inventors: Giuseppe Claudio VISCOMI, Ernesto PALAZZINI, Villiam ZAMBONI, Maria Rosaria PANTALEO
-
Publication number: 20140112981Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.Type: ApplicationFiled: December 3, 2013Publication date: April 24, 2014Applicant: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred P. Tonelli
-
Publication number: 20140112996Abstract: The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms.Type: ApplicationFiled: July 22, 2013Publication date: April 24, 2014Applicant: NEOS THERAPEUTICS, LPInventors: Mark TENGLER, Russell MCMAHEN